{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T23:03:02Z","timestamp":1772146982642,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.urolonc.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T20:45:19Z","timestamp":1509482719000},"page":"79.e1-79.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review"],"prefix":"10.1016","volume":"36","author":[{"given":"Yangyang","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhankui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaohui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-4500","authenticated-orcid":false,"given":"Jinjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.10.001_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2011.06.049","article-title":"The epidemiology of renal cell carcinoma","volume":"60","author":"Ljungberg","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2017.10.001_bib3","first-page":"E359","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2017.10.001_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11934-005-0062-x","article-title":"Surveillance following radical or partial nephrectomy for renal cell carcinoma","volume":"6","author":"Lam","year":"2005","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urolonc.2017.10.001_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2017.10.001_bib6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.1994.12.1.206","article-title":"Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy","volume":"12","author":"Rabinovitch","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0167-8140(97)01949-X","article-title":"Is post-operative radiation for renal cell carcinoma justified?","volume":"43","author":"Aref","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(92)90352-U","article-title":"The value of postoperative irradiation in renal cell cancer","volume":"24","author":"Stein","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib9","first-page":"1545","article-title":"Adjuvant immunotherapy in renal cell carcinoma\u2014comparison of interferon alpha treatment with an untreated control","volume":"19","author":"Basting","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2017.10.001_bib10","first-page":"5593","article-title":"The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma","volume":"19","author":"Jeon","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2017.10.001_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.2001.19.2.425","article-title":"Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study","volume":"19","author":"Pizzocaro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib12","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.2003.02.005","article-title":"Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group\/Intergroup trial","author":"Messing","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib13","first-page":"13","article-title":"Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines","author":"Kirchner","year":"1995","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib14","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P","article-title":"Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Gu\u00e8rin: five-year results of a prospective randomized study","volume":"77","author":"Galligioni","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.10.001_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.14712\/fb2003049020069","article-title":"Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial","volume":"49","author":"Doehn","year":"2003","journal-title":"Folia Biol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib16","first-page":"969","article-title":"Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis","volume":"23","author":"Repmann","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2017.10.001_bib17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0140-6736(04)15590-6","article-title":"Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial","volume":"363","author":"Jocham","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.urolonc.2017.10.001_bib18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.10.001_bib19","first-page":"2246","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","author":"Ravaud","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.urolonc.2017.10.001_bib20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/01.ju.0000159585.26331.77","article-title":"Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study","volume":"173","author":"MARSHALL","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib21","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2017.10.001_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin Res ed)"},{"key":"10.1016\/j.urolonc.2017.10.001_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ (Clin Res ed)"},{"key":"10.1016\/j.urolonc.2017.10.001_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.urology.2008.08.476","article-title":"Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma","volume":"73","author":"Margulis","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.10.001_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.10.001_bib26","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P","article-title":"Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study","volume":"77","author":"Galligioni","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.10.001_bib27","article-title":"Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial","author":"Chamie","year":"2016","journal-title":"JAMA Oncol"},{"issue":"37","key":"10.1016\/j.urolonc.2017.10.001_bib28","first-page":"440","article-title":"Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-alpha) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC)","volume":"2014","author":"Passalacqua","year":"1997","journal-title":"J Immunother (Hagerstown, Md"},{"key":"10.1016\/j.urolonc.2017.10.001_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10147-011-0345-9","article-title":"Randomized controlled study of natural interferon alpha as adjuvant treatment for stage II or III renal cell carcinoma","volume":"18","author":"Hinotsu","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2013.08.019","author":"Aitchison","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2017.10.001_bib31","doi-asserted-by":"crossref","first-page":"14586","DOI":"10.1200\/jco.2006.24.18_suppl.14586","article-title":"Adjuvant thalidomide improves disease specific survival for patients with renal cell carcinoma at high risk for relapse following surgery","author":"Sanchez-Ortiz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib33","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.urolonc.2017.10.001_bib34","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib35","first-page":"907","article-title":"Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?","volume":"14","author":"Patel","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.urolonc.2017.10.001_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2407-11-115","article-title":"Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis","volume":"11","author":"Scherr","year":"2011","journal-title":"BMC Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917305288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917305288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:12:42Z","timestamp":1761041562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917305288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1078143917305288"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.10.001","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}